Outcomes for transformed follicular lymphoma in the rituximab era: the Royal Marsden experience 2003-2013.

2017-08

Gleeson, Mary

Hawkes, Eliza A

Peckitt, Clare

Wotherspoon, Andrew

Attygalle, Ayoma

Sharma, Bhupinder

Du, Yong

Ethell, Mark

Potter, Mike

Dearden, Claire

Horwich, Alan

Chau, Ian

Cunningham, David

Follicular lymphoma

high-grade transformation

rituximab era

stem-cell transplantation

Journal Article

10.1080/10428194.2016.1265114

Survival for transformed follicular lymphoma (tFL) has improved in the rituximab era and the need for upfront stem cell transplantation (SCT) is unclear. We evaluated the outcomes for all patients treated with first-line chemotherapy for histologically-proven tFL at our institution from 2003-2013 (n = 87). The majority of patients (89.7%) did not receive a SCT as part of first-line management. With a median follow-up of 7.8 years the 5-year overall survival (OS) for all patients was 61.7%. Patients treated with R-CHOP without upfront SCT (n = 55/87) had a 5-year OS of 64.3%. In a Cox regression analysis of the entire cohort (n = 87) International Prognostic Index (IPI) risk group and presence of B symptoms at transformation were independently associated with OS in multivariate analysis (MVA). Our analysis confirms the improved survival of tFL in the rituximab era even in the absence of upfront SCT consolidation.

link

Leukemia & lymphoma 2017; 58(8): 1805-1813

Leukemia & lymphoma